埼玉医科大学雑誌 第47巻 第2号 (令和3年3月) 91-95頁◇論文(図表を含む全文)は,PDFファイルとなっています. PDF (786 KB) Shuji Momose2), Jun-ichi Tamaru2), Masahiro Kizaki1) 1)Department of Hematology, Saitama Medical Center, Saitama Medical University 2)Department of Pathology, Saitama Medical Center, Saitama Medical University Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma (TCL) of childhood rarely develops in adults. The first case of sys-temic EBV-positive TCL, which occurred in an adult patient with chronic myeloid leukemia who was treated with a tyrosine kinase inhibitor (TKI), is reported. The patient was treated with nilotinib (TKI) for two years. He presented with a two-month history of cervical lymphadenopathy, common cold symptoms and had high titers of EBV in peripheral blood. A lymph node biopsy showed CD8-positive atypical T cells with EBV infection. Because of the pathological finding of EBV-positive T-cell lymphoma and status of EBV reactivation, we diagnosed him with systemic EBV-positive TCL. Conventional chemotherapy followed by hematopoietic stem cell transplantation was a valuable therapeutic option for this patient. TKIs are likely to inhibit T-cell activation and prolifera-tion, and might be involved in the onset of systemic EBV-positive TCL. J Saitama Medical University 2021; 47(2): 91-95
|